Scandinavian Real Heart AB (HEART) AI Stock Analysis

• Market Cap: kr134.97M
• Dividend Yield: N/A
• Average Volume (3M): 7.92K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.07
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: SE
• Employees: 13
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): N/A
• Shares Outstanding: 9,997,408
• 10 Day Avg. Volume: 3,221
• 30 Day Avg. Volume: 7,918
• PEG Ratio: 0.03
• Price to Book (P/B): 1.11
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.20
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): kr42.00M

• Rating: 43 Neutral
• Price Target: kr13.50 ▼(-47.67% Downside)
• Action: Reiterated Date: 02/21/26
• Date: Action: Reiterated 02/21/26

The score is primarily weighed down by weak financial performance (minimal revenue, sustained losses, and ongoing cash burn). Technical indicators are mixed/neutral and do not provide strong support, while valuation inputs are limited and skew negative due to unprofitability and no dividend yield data.

Positive Factors

Clear product focus

The company is singularly focused on a total artificial heart for severe heart failure, a durable strategic position. If clinical and regulatory milestones succeed, the device targets a persistent, high-need patient population with long product lifetimes and recurring service opportunities, supporting multi-year commercial potential and strategic partnerships.

Negative Factors

Persistent cash burn

The company has recurring negative operating and free cash flow, indicating it cannot self-fund development. Over a multi-month horizon this necessitates external financing, increasing dilution risk, potentially delaying trials or commercialization if capital markets tighten, and placing pressure on strategic execution.

Scandinavian Real Heart AB Business Overview & Revenue Model

Company Description

Scandinavian Real Heart AB (Publ) designs and develops an artificial heart. It engages in developing Realheart TAH to treat advanced stage heart failure. It also develops RealVAD, PulsePump, and Sternal Prosthesis products. The company was incorpo...

Read more

Scandinavian Real Heart AB (Publ) designs and develops an artificial heart. It engages in developing Realheart TAH to treat advanced stage heart failure. It also develops RealVAD, PulsePump, and Sternal Prosthesis products. The company was incorpo...

How the Company Makes Money

Scandinavian Real Heart AB primarily generates revenue through the development and commercialization of its Total Artificial Heart technology. This involves securing partnerships with healthcare institutions and medical device distributors who fac...

Read more

Scandinavian Real Heart AB primarily generates revenue through the development and commercialization of its Total Artificial Heart technology. This involves securing partnerships with healthcare institutions and medical device distributors who fac...

Scandinavian Real Heart AB Financial Statement Overview

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	10.00K	0.00
Gross Profit	28.33M	-20.40M	-164.70K	-50.22M	12.29M	7.20M
EBITDA	-14.02M	-15.09M	-33.54M	-67.25M	-13.73M	-10.09M
Net Income	-38.87M	-35.50M	-34.35M	-67.98M	-13.99M	-10.48M
Balance Sheet
Total Assets	87.94M	72.69M	83.28M	102.64M	119.82M	117.82M
Cash, Cash Equivalents and Short-Term Investments	27.94M	16.57M	23.72M	43.30M	11.26M	42.67M
Total Debt	5.40M	4.46M	6.35M	8.25M	2.17M	2.80M
Total Liabilities	13.59M	10.20M	15.94M	20.60M	22.17M	6.53M
Stockholders Equity	74.35M	62.49M	67.34M	82.04M	97.65M	111.29M
Cash Flow
Free Cash Flow	-39.30M	-16.53M	-38.25M	-26.82M	-31.14M	-29.24M
Operating Cash Flow	-12.62M	-15.66M	-12.99M	-25.05M	-7.38M	-9.65M
Investing Cash Flow	-25.71M	-26.11M	-24.28M	-1.77M	-23.76M	-19.59M
Financing Cash Flow	43.44M	34.62M	17.69M	58.87M	-276.28K	49.46M

Scandinavian Real Heart AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 25.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:HEART, the sentiment is Negative. The current price of 25.8 is above the 20-day moving average (MA) of 13.56, above the 50-day MA of 13.84, and above the 200-day MA of 15.91, indicating a bearish trend. The MACD of -0.14 indicates Negative momentum. The RSI at 46.20 is Neutral, neither overbought nor oversold. The STOCH value of 32.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:HEART.

Scandinavian Real Heart AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
QLIFE	44 Neutral	kr62.40M	-1.73	437.24%	―	376.81%	97.95%
LXB	44 Neutral	kr46.85M	-2.89	-60.56%	―	163.12%	30.50%
SDOS	44 Neutral	kr56.90M	-8.36	―	―	―	―
HEART	43 Neutral	kr134.97M	-1.96	―	―	―	―
SPEC	43 Neutral	kr51.24M	-1.14	-50.21%	―	―	-108.64%